UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 Altimmune, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2726770 State or Other Jurisdiction of ...

Altimmune, Inc. (NASDAQ:ALT) Q4 2018 Earnings Conference Call April 2, 2019 8:30 AM ET Company Participants Paul Arndt - LifeSci Advisors Vipin Garg - Chief Executive Officer Will Brown - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Jerry Isaacson - ROTH Capital Partners Operator Greetings and welcome to the Altimmune, Inc. Fourth Quarter and Fiscal Year 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 ☐ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-32587 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 20-2726770 (State or other jurisdiction of incorporatio ...